HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

TUCSON, Ariz. , Feb. 26, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq